Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Net Cash Flow (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Net Cash Flow for 17 consecutive years, with -$3.6 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 228.57% to -$3.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $38.6 million through Dec 2025, up 237.86% year-over-year, with the annual reading at $38.6 million for FY2025, 237.86% up from the prior year.
  • Net Cash Flow for Q4 2025 was -$3.6 million at Myriad Genetics, down from $71.1 million in the prior quarter.
  • The five-year high for Net Cash Flow was $177.2 million in Q3 2021, with the low at -$92.6 million in Q1 2022.
  • Average Net Cash Flow over 5 years is $1.8 million, with a median of -$3.6 million recorded in 2023.
  • Peak annual rise in Net Cash Flow hit 1294.12% in 2025, while the deepest fall reached 1178.57% in 2025.
  • Over 5 years, Net Cash Flow stood at -$36.5 million in 2021, then dropped by 23.29% to -$45.0 million in 2022, then soared by 222.67% to $55.2 million in 2023, then plummeted by 94.93% to $2.8 million in 2024, then tumbled by 228.57% to -$3.6 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$3.6 million, $71.1 million, and -$17.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.